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Otosclerosis is a common form of progressive hearing loss, characterized by abnormal bone remodeling in the otic capsule. The etiology
of the disease is largely unknown, and both environmental and genetic factors have been implicated. To identify genetic factors involved
in otosclerosis, we used a case-control discovery group to complete a genome-wide association (GWA) study with 555,000 single-nucle-
otide polymorphisms (SNPs), utilizing pooledDNA samples. By individual genotyping of the top 250 SNPs in a stepwise strategy, wewere
able to identify two highly associated SNPs that replicated in two additional independent populations.We then genotyped 79 tagSNPs to
ﬁne map the two genomic regions deﬁned by the associated SNPs. The region with the strongest association signal, pcombined ¼ 6.23 3
1010, is on chromosome 7q22.1 and spans intron 1 to intron 4 of reelin (RELN), a gene known for its role in neuronal migration.
Evidence for allelic heterogeneity was found in this region. Consistent with the GWA data, expression of RELN was conﬁrmed in the
inner ear and in stapes footplate specimens. In conclusion, we provide evidence that implicates RELN in the pathogenesis of otosclerosis.Introduction
Hearing loss, the most frequent sensory impairment in
developed countries, profoundly impacts emotional, phys-
ical, and social well-being.1 One variety, otosclerosis (MIM
166800), is particularly common in the European popula-
tion, occurring with a reported frequency of 0.3%–0.4%.2
The hearing loss in otosclerosis typically begins in the
third decade and progressively becomes more severe,
reﬂecting pathognomonic abnormal bone remodeling of
the otic capsule. The remodeling process often involves
the stapediovestibular joint, and by interfering with
motion of the stapes, it leads to conductive hearing loss
and clinical otosclerosis. Histological otosclerosis is seen
nearly ﬁve timesmore frequently than clinical otosclerosis.
However, because stapes ﬁxation is absent, unless high-
resolution computed tomography of the temporal bones
is obtained, the diagnosis can only be made post-
mortem.2,3 Approximately 10% of persons with clinical
otosclerosis also develop sensorineural hearing loss.4,5
The etiology of otosclerosis remains unknown, although
several hypotheses implicate viral, immunological,
hormonal, and endocrine factors in disease development.
In addition, the familial clustering of persons with otoscle-
rosis indicates that genetic factors are also important.6,7
Otosclerosis is most appropriately considered as a complex328 The American Journal of Human Genetics 84, 328–338, Marchdisease caused by different environmental and genetic
factors. However, monogenic forms of otosclerosis also
exist.
For the identiﬁcation of genetic contributions to otoscle-
rosis, eight large families segregating monogenic otoscle-
rosis suitable for genome-wide linkage analysis have been
used in the mapping of eight otosclerosis loci, although
only seven of these localizations are published (OTSC1–
OTSC5, OTSC7, OTSC8).8–14 None of the genes have been
cloned. An alternative genetic approach, the candidate-
gene case-control association study, has been modestly
successful, and there is evidence that COL1A1 (MIM
120150), TGFB1 (MIM 190180), BMP2 (MIM 112261),
and BMP4 (MIM 112262) contribute to disease develop-
ment.15–17 Common to these four genes is a role in bone
and/or otic-capsule development and remodeling, but
the predictive genetic contribution of these genes to the
pathogenesis of otosclerosis is only minimal. An associa-
tion between otosclerosis and the renin-angiotensin-aldo-
sterone (RAA) system has also been suggested.18
New knowledge from the HumanGenome project, avail-
ability of high-density SNP maps via projects such as
HapMap, and technological progress in genotyping have
made it possible to perform genome-wide association
(GWA) studies. This approachdoesnot dependon the selec-
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of otosclerosis at the molecular level. It holds the
promise of identifying genes and pathways that are
causally related to otosclerosis but are not at this time
intuitively obvious. The power of this strategy has been
validated for a variety of other complex diseases. Because
GWA studies are still very expensive, we used pooled
DNA samples in a stepwise screening strategy to reduce
costs (Figure 1). This modiﬁcation is particularly useful
for identifying major genetic contributions to a given
disease.19
Subjects and Methods
Clinical Diagnosis
Pure-tone audiometry was performed on all patients, with air
conduction at 125, 250, 500, 1000, 2000, 4000, and 8000 Hz
and bone conduction at 250, 500, 1000, 2000, and 4000 Hz. To
exclude outer- or middle-ear pathology, otoscopy and tympano-
scopy were performed. The mobility of the stapes was assessed
via tympanometry and the measurement of stapedial reﬂexes.
Persons in whom otosclerosis was conﬁrmed during stapes micro-
surgery were considered affected. In persons who had not under-
gone surgery, the diagnosis of clinical otosclerosis was based on
audiometric data. Persons with a conductive or mixed hearing
loss together with absent or immeasurable stapedial reﬂexes
were classiﬁed as affected. Controls were not screened, because
with the known disease frequency of otosclerosis in the European
population, the loss of power is negligible.20
Study Populations
Individuals in a Belgian-Dutch group of case samples, consisting of
694 unrelated persons of Belgian or Dutch origin diagnosed with
otosclerosis, were recruited by the Department of Otolaryngology
in several hospitals: the University Hospital of Antwerp (Antwerp,
Belgium), St. Augustinus Hospital (Antwerp), the University
Hospital of Ghent (Ghent, Belgium), and the University Medical
Center St. Radboud (Nijmegen, The Netherlands). In 97.8% (n ¼
679) of these cases, the diagnosis of otosclerosis was conﬁrmed
during stapes microsurgery. The same number of unrelated
controls (n ¼ 694) were selected from a DNA repository of the
Department of Medical Genetics (Antwerp). All controls were
matched with cases according to sex, age (5 1 year), and ethnicity.The AmeFigure 1. Schematic Representation of the Staged Design
Used in This Study
Individuals with unknown family relationships and/or an
outlying genetic background were excluded from this popula-
tion in a previous study.17 A French group of case samples, con-
sisting of 455 unrelated persons of French origin diagnosed
with otosclerosis, was also collected, through the Jean Causse
Ear Clinic (Colombiers, France), and 480 unrelated control
samples, matched for ethnicity, were collected by the Labora-
toire de Genetique Moleculaire et Chromosomique IURC,
CHU Montpellier. In all French cases, the diagnosis of otoscle-
rosis was conﬁrmed at stapes microsurgery.
A discovery group and an independent replication set
were then created from the Belgian-Dutch population. The
discovery group comprised 302 cases and 302 controls of
Belgian origin. This group was used for the initial GWA study
with the creation of DNA pools of cases and controls. The ﬁrst
independent replication set comprised the remaining Belgian-
Dutch samples—392 cases and 392 controls. The French samples
were used as a second independent replication cohort. The demo-
graphics of each population are shown in Table S1 (available
online), and Figure 1 shows a general overview of the stepwise
strategy that was used in this study. Subsequent ﬁne mapping
was done with all Belgian-Dutch case-control samples.
This project was approved by the Ethical Committee of the
University of Antwerp, and informed consent was obtained from
each patient. Genomic DNA was extracted from fresh or frozen
blood, via standard techniques.21
Genome-wide Association
DNA quality was assessed with agarose gel electrophoresis and
spectrophotometric analysis; samples of poor quality were elimi-
nated. Quantiﬁcation was completed in triplicate with PicoGreen
(Molecular Probes, Eugene, Oregon, USA), ensuring the equality
of individual contributions to the pooled samples. From the 302
patients of the discovery group, three pools were constructed
independently, in triplicate, from all individual samples, ensuring
that pipetting variation was normalized. In total, 70 ng of DNA
from each individual contributed to each pool, and each pool
was diluted with water to a target concentration of 50 ng/ml.
The same was done for the 302 controls of the discovery group.
From each pool (six in total), 750 ng was hybridized to an indi-
vidual Illumina HumanHap550 SNP chip, in accordance with
the manufacturers’ protocol for individual genotyping. This
chip used the Inﬁnium II Assay to interrogate over 555,000
SNPs on a single BeadChip. We chose the Illumina platform,
because it was previously shown that of the two main array
platforms available for pooling, Illumina is more efﬁcient than
Affymetrix.22
Data Analysis of DNA Pools
We normalized red and green intensities by dividing them by the
overall mean intensity value of the red or green channel. Outlying
SNPs with zero intensities or SNPs represented by an abnormally
low number of beads (<5) were removed. Differences in allelic
frequency were detected by assessment of bead intensity. Data
were ranked with GenePool software by silhouette statistics,
a process which has been described in detail elsewhere.19rican Journal of Human Genetics 84, 328–338, March 13, 2009 329
Individual Genotyping
From genome-wide data ranked by Genepool software, 250 SNPs
were chosen from the samples used for constructing the pools
(the discovery group) for validation by individual genotyping.
These 250 SNPs included the top 200 ranked SNPs from the pool-
ing data and 50 additional SNPs chosen on the basis of two
different strategies: First, 28 SNPs were chosen from the top
3000 on the basis of their genetic position (i.e., in the OTSC
loci) or proximity to genes that we considered possibly relevant
to the pathogenesis of otosclerosis on the basis of prior reports.
Second, 22 SNPs were selected from the top 1000 on the basis of
close location to another SNP from the top 1000 (<20,000 bp
from the next SNP). All SNPs that showed a signiﬁcant association
were then selected for genotyping in the ﬁrst independent replica-
tion set (784 samples). SNPs that showed the same signiﬁcant
effect in both the discovery group and the ﬁrst replication set
were genotyped in the second replication set (935 samples). Gen-
otyping was performed by KBioscienses (Herts, UK), via a form of
allele-speciﬁc PCR referred to as KASPar.
Fine Mapping
The SNPs that showed a signiﬁcant effect in the same direction in
all three sets were selected for ﬁne mapping. This step was done
because it not only provides a more complete overview of the
associated region, it also allows determination of whether the
signiﬁcant SNP represents one signal or whether there are several
independent signals. Fine mapping was performed in all Belgian-
Dutch case-control samples. TagSNPs were selected in the regions
surrounding the signiﬁcant SNPs on the basis of LD structure
provided by CEPH genotype data (HapMap, release 21a, phase
II), with the use of the aggressive algorithm of Tagger (single
marker and multimarker predictions),23 implemented in Haplo-
view (version 4.0, beta 15).24 The minor-allele frequency was set
to 0.05, and an r2 cutoff of 0.8 was chosen. Some of the most
signiﬁcant SNPs from the ﬁne mapping data were genotyped in
the second replication set; genotyping was again performed by
KBioscienses.
Quality-Control Measures
Samples with a poor call rate (>10% missing) were excluded from
the analysis. If only a few SNPs were genotyped, as in the second
replication set (11 SNPs), the cutoff was rounded off to the nearest
integer. After removal of samples with a poor call rate, SNPs with
a bad call rate (>4%missing calls) were excluded. Hardy-Weinberg
equilibrium (HWE) was calculated in controls, and SNPs with
a p value < 0.001 were excluded.25
Association Testing
Data were handled with SAS/Genetics 9.1 (SAS Institute, Cary, NC,
USA). All analyses were performed via automated procedures in R
(version 2.3.1) and SPSS 15.0 (SPSS, Chicago, IL, USA).
To test the single-SNP association, we performed a 1 df likeli-
hood ratio test (LRT) using logistic regression. Here, the genotype
was coded linearly, under the assumption that the odds of disease
increases multiplicatively for every copy of the disease allele (here
referred to as an additive model). Multimarker prediction (MMP)
tests, using speciﬁc combinations of two or three SNP alleles
(haplotypes) serving as a proxy for an untyped SNP, as provided
by the Tagger program,23 were performed via the haplotype proce-
dure implemented in SAS/Genetics 9.1. For each MMP, we tested330 The American Journal of Human Genetics 84, 328–338, Marchthe speciﬁc haplotype predicting the hidden SNPs versus all other
haplotypes combined.
To check whether the disease-associated allele has the same
genetic effect across the populations, we ﬁtted a logistic-regression
model, including genotype, population, and the population 3
genotype interaction. This interaction term indicates a difference
in effect according to population.We performed an LRT to test the
term’s signiﬁcance. Nonsigniﬁcance of the interaction term indi-
cates that the effect of the SNP on disease susceptibility is not
signiﬁcantly different between the populations. In this case, we
ﬁtted a reduced logistic-regression model that included only the
main effects for genotype and population. In this way, the
common genetic effect across the populations was estimated.
The common OR and its 95% Wald CI were estimated by the
regression coefﬁcient for genotype and its large-sample CI, respec-
tively. The p values for the common genetic effect were obtained
through an LRT comparing a model including population and
genotype to a model including only population as a predictor.
Allelic Heterogeneity
The availability of several SNPs in the two ﬁne-mapped regions
allowed testing for allelic heterogeneity. We included data from
both the discovery group and the ﬁrst independent replication
set to increase power. We also tested for allelic heterogeneity in
the second independent replication set (the French population)
over the chr7q22.1 region, although there were fewer available
SNPs.
Allelic heterogeneity was tested in a logistic-regression frame-
work. In each region, we checked whether the most signiﬁcant
SNP alone was sufﬁcient to account for all signiﬁcant associations.
One by one, each SNP was added to a model containing only the
most signiﬁcant SNP in each region. We used an LRT to test
whether adding the second SNP signiﬁcantly improved the model
ﬁt. If another SNP added signiﬁcance in the model already con-
taining the most signiﬁcant SNP, we performed a reverse analysis
to conﬁrm that the two effects were independent. To test whether
a third signal existed in the region, we added each of the remain-
ing SNPs one by one to a model containing the two independent
SNPs.
To test for interaction between the two independently signiﬁ-
cant SNPs (rs3914132 and rs7791481), we ﬁtted a logistic-
regression model including both genotypes and a genotype
rs39141323 genotype rs7791481 interaction term.We performed
an LRT to test the signiﬁcance of the interaction term.
RT-PCR
Tissues from wild-type and Relnrl (MIM 600514) knockout mice
from B6C3Fe a/a-Relnrl/J heterozygous breeding pairs were
collected and stored in RNAlater reagent (Ambion, Austin, TX,
USA). Total RNAwas extracted frommouse tissues with the Rneasy
Mini kit (QIAGEN, Valencia, CA, USA), in accordance with the
manufacturer’s protocol. Human stapes samples were collected
from patients undergoing translabyrinthine surgery for vestibular
schwannoma. The footplate of each sample was separated from
the stapes and preserved in liquid nitrogen. Stapes footplate
samples were disrupted and homogenized in 1 ml QIAzol Lysis
Reagent. Total RNA was extracted with the RNeasy Lipid Tissue
Mini Kit (QIAGEN), in accordance with the manufacturer’s
protocol.
Reln and the known associated genes Dab1 (MIM 603448), Vldlr
(MIM192977), and Lrp8 (MIM602600) were ampliﬁed from cDNA13, 2009
with gene-speciﬁc primers. First, cDNA synthesis was performed
with the High Capacity Reverse Transcriptase kit (Applied Biosys-
tems, Foster City, CA, USA), in accordance with themanufacturer’s
protocol. We performed PCR ampliﬁcation of cDNA by amplifying
across exon-exon junctions of each gene for both mouse and
human samples under the following PCR conditions: 95C for
5 min; 35 cycles of 95C for 30 s, 55C for 30 s, and 72C for
45 s; and 72C for 10 min. Gapdh (MIM 138400) served as a posi-
tive control, and samples extracted from the Relnrl knockout mice
served as a negative control.
Western Blot
Tissues were dissected from postnatal day 28 (P28) wild-type and
Relnrl knockout mice littermates from B6C3Fe a/a-Relnrl/J hetero-
zygous breeding pairs. The tissues were disrupted by homogeniza-
tion in lysis buffer (1 mM DTT, 5 mM EDTA, and protease inhibi-
tors in PBS). Protein was isolated by centrifugation of total
homogenate for 10 min at 13,000 rpm at 4C. Protein was quanti-
ﬁed with the BCA assay (Sigma, St. Louis, MO, USA). Equal
amounts of protein were prepared in sample buffer containing
b-mercaptoethanol and heated at 100C for 5 min, then run on
7.5% SDS-PAGE gels for 1.5 hr at 100 V. Proteins were transferred
to nitrocellulose membrane, then blocked in 5%milk in TBS-T for
1 hr at room temperature. Membranes were incubated overnight
at 4C in 1:500 dilution primary antibody (G10 mouse anti-
reelin), followed by a 3 hr incubation in 1:5000 dilution of goat
anti-mouse IgG conjugated with horseradish peroxidase.
Membranes were washed and developed with the SuperSignal
West Pico Chemiluminescent Substrate Kit (Pierce, Rockford, IL,
USA). Samples from the Relnrl knockout mice served as a negative
control.
Real-Time PCR
Expression of Reln in the inner ear was investigated in mice at
several time points after birth in relation to brain and liver, where
the gene is highly expressed.26 Inner ear (with surrounding carti-
lage), liver, and whole brain were dissected from eight outbred
Swiss OF1 mice of different stages (newborn, P3, P6, P20, and
P30; all from the same breeding pair) and stored immediately in
liquid nitrogen. After homogenization, total RNA was isolated
with Trizol (Invitrogen, Carlsbad, CA, USA), in accordance with
the manufacturer’s instructions. All samples were DNase treated
with the DNA-free kit (Ambion). cDNA synthesis was done in
duplicate with random hexamer primers with the Superscript III
ﬁrst-strand synthesis system for reverse transcriptase PCR (RT-
PCR) (Invitrogen). For quantitative real-time PCR, TaqMan Gene
Expression Assays (Applied Biosystems) for Reln and two house-
keeping genes (Ubc [MIM 191340] and Hprt1 [MIM 308000])
were used. The probes for all assays were designed to span an
exon junction. Mixtures consisted of 5 ml LightCycler 480 Probes
Master (2x; Roche, Basel, Switzerland), 0.5 ml TaqMan Assay, and
2.5 ml water (PCR grade; Roche) and were run on a LightCycler
480 Instrument (Roche). The cycling conditions were as follows:
10 min at 95C and 40 cycles at 95C for 10 s and 60C for 1 min.
Analysis was done with qBaseplus (Biogazelle, Zulte, Belgium).27
We calculated the coefﬁcient of variance (CV) and the M value of
housekeeping genes to determine the stability of their expression.
We calculated normalized values using stably expressed house-
keeping genes. The geomean of each group was calculated for
graphical representation of the results.The AmerTo conﬁrm the highly variable expression of Reln in the inner
ear, we extracted RNA from the inner ears of 15 extra mice at
P20 and 16 extra mice at P30. Each stage group was from the
same litter of the same breeding pair. Quantiﬁcation was done
via a one-step RT-PCR system (TaqMan RNA-to-CT 1-Step Kit;
Applied Biosystems), in accordance with the manufacture’s
protocol. We used 60 ng of DNase-treated RNA for ampliﬁcation,
and we analyzed each sample in duplicate. Analysis of the results
was performed as described above.
Results
Genome-wide Association and Validation
DNA pools of patients and controls were subjected to GWA
analysis with 555,000 SNPs (Figures S1 and S2). A ranked
list of all SNPs was obtained from the analysis of probe-
intensity differences using silhouette statistics. The silhou-
ette scores of the top-ranked SNPs are shown in Table S2.
The 250 SNPs from the pooling study were subsequently
genotyped on the individual samples used to make the
discovery group pools.
After quality control, 230 SNPs were analyzed, and of
these, 196 SNPs generated a p value < 0.05 (ranging from
4.62 3 107 to 0.05; Figure S3 and Table S2), demon-
strating that the pool-screening step was highly successful.
Of the 196 SNPs, 16 generated a signiﬁcant p value in the
ﬁrst independent replication set (784 samples), with
11 SNPs showing the same effect in both populations
(Table 1). The SNPs rs112578 and rs4467276 are in LD
with each other (r2 ¼ 1; D0 ¼ 1).25
These 11 SNPs were analyzed in the second independent
replication set, with two SNPs showing a signiﬁcant p value
in this population. The ﬁrst SNP, rs3914132 (p ¼ 0.003;
OR: 1.425 [1.129–1.799]), is located on chr7q22.1; the
second SNP, rs670358 (p ¼ 0.005; OR: 0.640 [0.466–
0.878]), is located on chr11q13.1. Both of these SNPs
showed the same effect in all populations tested (homoge-
neity test: 0.486 and 0.968, respectively, over all three
populations; Table 2).
Fine Mapping
The areas containing the two associated SNPs were ﬁne
mapped, for deﬁnition of the regions associated with
otosclerosis. For the chromosome 7q22.1 region, 46
tagSNPs were selected over a 182,227 bp region
surrounding SNP rs3914132 (Figure 2, Figure S4). The
region was selected on the basis of the extent to which
the LD spread (Figure S4).25
For the chromosome 11q13.1 region, 33 TagSNPs were
selected in a 420,226 bp region surrounding the original
SNP (Figure 3).25 This SNP is located between two regions
of high LD and shows LD with both regions. Therefore,
we included both regions to identify where the association
signal maps.
Fine-mapping results for chromosomes 7q22.1 and
11q13.1 are listed in Table 2 and shown graphically in
Figures 2 and 3. Both regions showed several SNPs thatican Journal of Human Genetics 84, 328–338, March 13, 2009 331
Table 1. Eleven Significant SNPs with the Same Effect in the Discovery Group and the First Replication Set
SNP Chr. Gene
p Value
(DG)a
p Value
(RS1)b
Homogeneity
Testc
p Value Common
Genotype Effectc OR [95% CI]c
rs3914132 7q22.1 RELN 1.00 3 104 0.003 0.403 1.22 3 106 1.631 [1.335–1.993]
rs1112578 2q32.2 2.80 3 104 0.004 0.493 4.34 3 106 0.691 [0.590–0.810]
rs4667276 2q32.2 0.001 0.002 0.690 6.91 3 106 0.697 [0.594–0.817]
rs17761499 16q23.2 CDYL2 8.89 3 105 0.017 0.200 1.05 3 105 1.470 [1.237–1.748]
rs11243426 9q34.13 0.002 0.016 0.463 1.11 3 104 1.409 [1.183–1.679]
rs4603268 11q21 MAML2 0.002 0.033 0.347 2.42 3 104 1.367 [1.156–1.617]
rs2246288 10q26.3 INPP5A 0.006 0.016 0.766 2.56 3 104 0.683 [0.556–0.840]
rs4246059 6p25.2 MYLK4 0.006 0.015 0.686 2.57 3 104 1.335 [1.143–1.560]
rs10485428 6q12 BAI3 0.003 0.039 0.345 5.23 3 104 1.671 [1.245–2.244]
rs670358 11q13.1 0.028 0.022 0.909 0.001 0.670 [0.522–0.860]
rs2330247 21q22.3 0.022 0.046 0.773 0.002 0.723 [0.585–0.893]
a p value in the discovery group.
b p value in the first replication set.
c Combined data of discovery group and first replication set.were signiﬁcant in the discovery group and/or the ﬁrst
independent replication set. In addition, several MMPs
were signiﬁcant in the chromosome 7q22.1 region but
not in the chromosome 11q13.1 region (data not shown).
Two of the most interesting MMPs (p % 0.0001: rs39335
and rs39395) were genotyped individually as a validation.
For the chromosome 11q13.1 region, all of the signiﬁcance
was localized to the region of high LD telomeric to the orig-
inal SNP (Figure 3).
SNPs that were signiﬁcant in both groups and had the
same effect in both groups (data not shown) were geno-
typed in the second independent replication set (Table 2).
For the chr7q22 region, several SNPs were signiﬁcant in
the same direction (homogeneity test). In the chr11q13
region, with exception of the original SNP, none of the
other SNPs replicated. The allele frequencies across all
HapMap populations for the SNPs on chr7q22 were very
similar (for example, rs39395 minor-allele frequency:
0.44 5 0.03 and rs3914132 minor-allele frequency:
0.175 0.01; HapMap draft release no. 1, phase III).
Allelic Heterogeneity
To determine whether all signiﬁcant signals were, through
LD, attributable to one or more underlying causative
variants, we tested each region for allelic heterogeneity
(Table 3). In the chromosome 7q22.1 region, rs3914132
was the most signiﬁcant SNP. When adding rs3914132 to
a regression model containing one of the other SNPs, we
saw that rs3914132 added signiﬁcance to all other SNPs.
Conversely, several, though not all, of the other SNPs
were no longer signiﬁcant when added to a regression
model already containing rs3914132. Their signiﬁcance
is probably due to LD with the same underlying variant
that rs3914132 is in LD with. On the other hand, many
other SNPs remained signiﬁcant even when the effect of
rs3914132 was accounted for, suggesting the presence of
more than one independent association signal. To analyze
howmany independent association signals the region con-332 The American Journal of Human Genetics 84, 328–338, Marchtained, we built a regression model with both rs3914132
and rs7791481 (r2: 0.004; D0: 0.439), adding each of the
remaining SNPs. We chose rs7791481 because it has
a strong association signal and is independently associated
with disease. An LRT showed that none of the remaining
SNPs added signiﬁcance to this model. Hence, there was
no statistical evidence of a third SNP with independent
effects. There was weak evidence for interaction between
rs3914132 and rs7791481 (p ¼ 0.04) (Table S3). In the
ﬁtted regression model, the regression coefﬁcient for inter-
action was negative, suggesting a less-than-additive effect.
In the French population, rs39395 was themost signiﬁcant
SNP. None of the other SNPs added signiﬁcantly to this
SNP, suggesting no evidence for allelic heterogeneity in
the genomic region tested (data not shown).
In the chr11q13.1 region, no evidence for allelic hetero-
geneity was found (data not shown).
RELN Expression in the Stapes Footplate
and the Inner Ear
RT-PCR
Expression analysis via RT-PCR showed that reelin mRNA
is expressed in both mouse and human ear structures
(Figures 4A and 4B). Expression of Reln was detected in
the cochlea of P6 mice, along with the known adaptor
protein Dab1 and two known receptors for reelin, Lrp8
and Vldlr. RELN expression was also detected in human
stapes footplate samples collected from patients who
were undergoing translabyrinthine surgery for vestibular
schwanoma and did not have otosclerosis.
Western Blot
Reelin was detected by western blot analysis of P28 mouse
inner ear (Figure 4C). As compared to brain, all three major
bands (420 kDa, 310 kDa, and 180 kDa) of Reln were
detected by the G10 antibody in mouse inner ear. A
nonspeciﬁc lower-molecular-weight band detected on
western blot was also present when blots were probed
with secondary antibody alone.13, 2009
Table 2. Results from Fine Mapping
SNP Positiona Gene
p Value
(DG)b
p Value
(RS1)c
p Value
(RS2)d
Homogeneity
Teste
p Value Common
Genotype Effecte OR [95% CI]e
chr7q22.1
rs2283029 28581795 RELN 0.009 0.695
rs17290575 28585197 RELN 0.374 0.021
rs262341 28602125 RELN 0.003 0.091
rs2299383 28602422 RELN 0.026 0.026 0.216 0.583 0.001 0.824 [0.732–0.928]
rs262355 28609691 RELN 0.015 0.536
rs17133096 28621061 RELN 0.566 0.023
rs11761011 28623116 RELN 0.007 0.745
rs39335f 28637145 RELN 0.017 0.022 0.143 0.561 5.39 3 104 0.741 [0.625–0.879]
rs39346 28649844 RELN 2.87 3 104 0.768
rs39347 28650074 RELN 0.019 0.779
rs39350 28650843 RELN 0.001 0.024 8.65 3 104 0.611 3.40 3 107 1.367 [1.212–1.543]
rs39374 28660243 RELN 2.04 3 105 0.048 2.13 3 105 0.160 1.55 3 109 1.441 [1.279–1.624]
rs12536007 28665264 RELN 0.219 0.049
rs39395f 28673305 RELN 2.00 3 104 0.011 7.23 3 106 0.399 6.23 3 1010 0.685 [0.607–0.773]
rs39399 28673568 RELN 1.66 3 105 0.077
rs13223714 28673996 RELN 0.011 0.315
rs1510858 28676484 RELN 0.708 0.034
rs39401 28678969 RELN 2.50 3 104 0.204
rs7791481 28688422 RELN 0.010 0.037 0.052 0.746 1.62 3 104 1.394 [1.171–1.658]
rs2237641 28703347 RELN 0.221 0.045
rs3914129 28710441 RELN 0.017 0.302
rs3914132g 28710945 RELN 1.00 3 104 0.003 0.003 0.486 1.69 3 108 1.540 [1.323–1.793]
rs802786 28729984 RELN 0.016 0.061
chr11q13.1
rs670358g 9897474 CDC42BPG 0.028 0.022 0.005 0.968 2.38 3 105 0.658 [0.541–0.801]
rs494252 9905797 CDC42BPG 0.034 0.016 0.110 0.781 4.27 3 104 1.394 [1.157–1.679]
rs627497 9944958 EHD1 0.010 0.015 0.184 0.406 3.82 3 104 1.355 [1.145–1.604]
rs7949144 9964194 0.031 0.223
rs616322 9996670 0.001 0.017 0.065 0.409 2.20 3 105 1.458 [1.223–1.739]
SNPs significant in the discovery group and/or replication set 1 are listed. The most significant signal in each region is shown in bold
a The following nucleotide reference sequences were used: for chr11, NT_033903.7; for chr7, NT_007933.14.
b p value in the discovery group.
c p value in replication set 1.
d p value in replication set 2.
e Combined data of all populations (discovery group, first and second replication set).
f Originally captured as an MMP, but also genotyped after very significant predictions.
g Originally identified SNP by the whole-genome association study.Real-Time PCR
Comparative expression of Reln in the inner ear, brain, and
liver showed that Reln expression is highest in the brain. It
peaks during development and then decreases after birth
(Figure 5). This is consistent with earlier reports describing
RelnmRNA expression in the brain during development.28
Although expression in the inner ear was 12-fold less than
in the brain at P0, reelin inner ear expression increased
after birth and was 7-fold less than brain expression at P3
and 4-fold less at P6. After P20, inner ear expression of
reelin was highly variable. We conﬁrmed this variability
by analyzing inner ears from31 additionalmice (Figure S5).
Variation in expression was not sex dependent.
Discussion
By using pooled DNA samples in a GWA study, we were
successful in identifying a region on chr7q22.1 that isThe Amestrongly associated with otosclerosis. To our knowledge,
this region has not previously been published. These
results are of interest because the prior associations with
COL1A1, TGFB1, BMP2, BMP4, and the RAA system
account for only a small fraction of the relative risk for
otosclerosis. This study also illustrates the value of pooling
DNA samples as the ﬁrst screening step in a GWA study.
Approximately 85% of 230 highly ranked SNPs identi-
ﬁed by pooling were validated as true differences between
cases and controls by individual genotyping of the
discovery group (p values ranging from p ¼ 107 to p ¼
0.05) (Table S2). In addition, the region with the strongest
association, on chromosome 7q22.1, included six of the
top 1000 SNPs identiﬁed in the pooling step (data not
shown). Noteworthy is that the originally identiﬁed SNP
(rs3914132) in this region was not in the top 200 ranked
SNPs and was actually included in the validation list
because its location was close to other SNPs in the toprican Journal of Human Genetics 84, 328–338, March 13, 2009 333
1000. Thus, pooling of DNA samples can be considered
a cost-effective strategy to screen for genetic associations
with a case-control study design, provided that there are
suitable conﬁrmatory stages in the experimental design.
In the staged design that we used, we selected the initially
identiﬁed variants for replication, a strategy that has been
shown previously to be very powerful and efﬁcient
(Figure 1).29
The strongest association signal that we found was on
chromosome 7q22.1 (Table 2). The originally identiﬁed
SNP was located in a large region of high LD that spreads
from intron 1 to intron 4 of the RELN gene (Figure 2,
Figure 2. Fine Mapping of the
chr7q22.1 Region in the Belgian-Dutch
Population
Significance is spread over the whole
region. The strength of LD (r2 value) is
shown in shades of gray. The originally
identified SNP is indicated by an asterisk.
The LD structure is based on CEPH genotype
data (HapMap release 21a, phase II).
Figure 3. Fine Mapping of the
chr11q13.1 Region in the Belgian-Dutch
Population
All of the significance is located in the
region of high LD telomeric to the original
SNP (right LD block). The strength of LD
(r2 value) is shown in shades of gray. The
originally identified SNP is indicated by
an asterisk. Seventeen genes or gene
predictions are located in this region
(based on NCBI build 36). The LD structure
is based on CEPH genotype data (HapMap
release 21a, phase II).
Figure S4).25 This entire region, of
approximately 180,000 bp, was cho-
sen for ﬁne mapping, and several
SNPs across this entire region showed
a strong association signal with
otosclerosis. Testing for allelic hetero-
geneity suggested that there are two
causal variants captured by either
SNP rs3914132 or SNP rs7791481.
The LD between these SNPs was
rather low (Table 3),25 which also
suggests that the signiﬁcance of the second signal is not
due to LD with the ﬁrst signal. Analysis of the interaction
between these two causal variants suggests that their
actions are less than additive. We were unable to conﬁrm
the presence of a second disease-causing signal in the
second independent replication group (the French popula-
tion), possibly because this signal was not captured by the
limited number of SNPs analyzed in this population.
The gene containing the association signal is RELN.
Reelin has a crucial role in the regulation of neuronal
migration and positioning in brain development.30 Its
known functions are difﬁcult to relate to otosclerosis,334 The American Journal of Human Genetics 84, 328–338, March 13, 2009
Table 3. Allelic Heterogeneity in the Complete Belgian-Dutch Population
chr7q22.1 SNPs p Valuea
LD with rs3914132b Single-Locus
Test when
SNP Added
to rs3914132
Single-Locus
Test when
rs3914132
Added to SNP
Single-Locus
Test when
SNP Added to rs3914132
and rs7791481D0 r2
rs17290575 0.020 0.490 0.213 0.661 1.92 3 105 0.361
rs262341 0.001 1.000 0.190 0.034 1.82 3 105 0.162
rs2299383 0.002 0.807 0.386 0.099 5.39 3 105 0.969
rs262355 0.040 0.874 0.148 0.257 4.92 3 106 0.502
rs17133096 0.032 0.572 0.005 0.087 1.57 3 106 0.142
rs11761011 0.031 0.598 0.014 0.076 1.99 3 106 0.169
rs39335 0.001 0.926 0.593 0.903 3.65 3 104 0.599
rs39346 0.008 1.000 0.085 0.115 7.34 3 106 0.326
rs39350 1.11 3 104 1.000 0.161 0.020 2.84 3 104 0.189
rs39374 1.63 3 105 1.000 0.135 0.014 0.001 0.214
rs12536007 0.023 1.000 0.028 0.060 4.46 3 106 0.121
rs39395 1.56 3 105 1.000 0.399 0.054 7.89 3 104 0.866
rs39399 2.86 3 105 1.000 0.175 0.027 3.21 3 104 0.309
rs13223714 0.014 1.000 0.090 0.002 1.26 3 107 0.384
rs39401 8.05 3 104 1.000 0.131 0.062 3.37 3 105 0.315
rs7791481 0.001 0.439 0.004 8.75 3 104 1.11 3 106 NA
rs2237641 0.021 1.000 0.024 4.71 3 104 6.03 3 108 0.213
rs3914129 0.018 1.000 0.190 0.325 3.09 3 105 0.980
rs3914132 1.23 3 106 NA NA NA NA NA
rs802786 0.003 0.890 0.792 0.229 4.50 3 105 0.277
NA denotes not applicable
a p value with the discovery group and first replication set (complete Belgian-Dutch population) lumped together.
b Values based on HapMap release 21a, Phase II.making it unclear how this gene could be involved in the
disease. However, we demonstrated expression of RELN
mRNA in human stapes footplate samples (Figure 4B),
and this supports the GWA ﬁndings. In addition, two
public human fetal cochlear cDNA databases, the Morton
Human Fetal Cochlea cDNA Library EST Database (dbEST
Library ID.371)31 and the Subtracted Human Cochlear
Library EST Database (dbEST Library ID 1822), report reelin
expression. Both databases derive results from cochleae of
human fetuses of 16–22 weeks gestational age. Only
membranous portions of the labyrinth were included;
surrounding bony and cartilaginous elements were
excluded.31
Expression of Reln mRNA was also detected in the
membranous part of the cochlea of mice, together with
known adaptor protein Dab1 and two known receptors
for reelin, Lrp8 and Vldlr (Figure 4A). Ikeda and colleagues
have noted embryonic expression at E12.5 in the
Figure 4. Reelin Expression in Inner Ear
and Stapes Footplate
(A) RT-PCR analysis of P6 mouse cochlea
(membranous part). P denotes postnatal
day.
(B) RT-PCR analysis of adult human stapes
footplates.
(C) Western blot analysis of P28 mouse
brain and the complete inner ear
(including surrounding cartilage). The
arrow head indicates a nonspecific band
detected by the secondary antibody.The American Journal of Human Genetics 84, 328–338, March 13, 2009 335
precartilage temporal bone primordial.26 In addition, we
followed Reln expression in the complete inner ear (with
surrounding cartilage) of mice at different stages of devel-
opment after birth (newborn, P3, P6, P20, and P30)
(Figure 5). We were able to show increased expression
shortly after birth, although by P20 and P30, expression
was highly variable. Because the strain that we used for
expression analysis was outbred and all mice were exposed
to the same environment, this variability probably reﬂects
genetic factors.32 It is remarkable that this variable expres-
sion is only present in the inner ear and not in the brain or
liver, suggesting that the inﬂuence of genetic factors on
expression is tissue speciﬁc.
We also demonstrated reelin protein expression in the
P28 murine inner ear (with surrounding cartilage;
Figure 4C). As reelin is secreted into the extracellular
matrix, it is processed by metalloproteinases, which create
several cleavage products.33 For example, in embryonic
and adult brain extracts and body ﬂuids, almost no full-
length reelin is detected.34 The products that we observed
in the inner ear have been described previously.33 In addi-
tion, reelin protein was recently identiﬁed in cochleae
from rats treated with the chemotherapeutic drug
cisplatin.35 In this study, reelin protein was upregulated
in response to cisplatin treatment, suggesting a prosurvival
response. Evidence for a prosurvival response through the
PI3K-Akt pathway has been demonstrated and might play
a role in the survival of hair cells in rats treated with
cisplatin.36Whether reelin acts under a similar mechanism
in the otic capsule is unknown.
Although there is compelling evidence to suggest that
the causative SNP is located in the gene RELN, it is also
possible that this SNP inﬂuences a regulatory element for
a neighboring gene and that RELN is not implicated in
otosclerosis.37 However, RELN is a very large gene, and
neighboring genes are located a great distance from the
associated region. For example, the gene neighboring
RELN proximally is SLC26A5, encoding the prestin protein
(MIM 604943), in which mutations have been associated
with nonsyndromic sensorineural hearing loss.38 Prestin
is a motor protein that is highly and almost exclusively
expressed in the outer hair cells (OHCs) of the cochlea.39
The associated region of high LD in RELN is located about336 The American Journal of Human Genetics 84, 328–338, March 1Figure 5. Expression Levels of Reln in Mice at Different
Time Points after Birth
P denotes postnatal day. The error bars indicate SEM.
310,000 bp upstream of this gene, and LD with this
gene is very low (Figure S4),25 but it cannot be excluded
that regulatory elements for this gene are located in the
associated region in RELN.37
Correction for multiple testing was difﬁcult in this
study because a staged design was used. When
a genome-wide Bonferonni correction for 555,000
markers (number of SNPs on the Illumina Human-
Hap550 SNP chip) is used, a p value below 9.01 3 108 is
considered signiﬁcant. The association on chromosome
7q22.1 survives this correction, but the association on
chromosome 11q13.1 does not. However, the latter associ-
ation was replicated independently twice, and replication
in independent populations is generally considered
a stronger conﬁrmation of an association than a very low
p value.40 In addition, a GWA study using pooled samples
is considered to be an initial screening step, making the
Bonferonni correction too conservative for this type of
study.41
It is also worth considering regions that replicated only
once (Table 1). Because we limited testing to the originally
identiﬁed variant, it is possible that for a few SNPs, we
might have overlooked replication that resulted from
allelic heterogeneity, differences in environmental factors,
other genetic factors, or differences in LD structure in some
regions.40,42,43 Testing additional markers in such regions
might identify additional regions that are truly associated
with otosclerosis.
In summary, we report a new strong association with
otosclerosis on chromosome 7q22.1. This region is located
in the gene RELN, and this association has not, to our
knowledge, been previously identiﬁed. Our data are consis-
tent with more than one variant of RELN being causally
related to otosclerosis and having a role in otosclerosis,
given that RELN expression was found in human stapes
footplates samples and in human and mouse inner ear.
Although it is true that the function of RELN known today
is difﬁcult to reconcile with our understanding of the path-
ogenesis of otosclerosis, perhaps this ﬁnding will help us
reevaluate in a new light the molecular mechanisms that
lead to this disease.
Supplemental Data
Supplemental Data include ﬁve ﬁgures and three tables and can be
found with this article online at http://www.ajhg.org/.
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